RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced the publication of the first genetically modified mammals using Precision’s Directed Nuclease Editor (DNE) engineered meganuclease technology. In a paper published in The FASEB Journal entitled “Generation of Rag1-knockout Immunodeficient Rats and Mice using Engineered Meganucleases,” researchers describe, for the first time, the application of DNE genome editing nucleases to generate rats with a desired gene permanently disabled or ‘knocked-out.’
“We are thrilled that our collaborators at Centre National de Recherche Scientifique and genOway were able to utilize the technology to efficiently generate an important research model.”
“This paper demonstrates the broad applicability and exquisite precision of our DNE technology for mammalian genome engineering,” said Derek Jantz, Precision BioSciences’ Vice President of Scientific Development. “We are thrilled that our collaborators at Centre National de Recherche Scientifique and genOway were able to utilize the technology to efficiently generate an important research model.”
“We are pleased that Precision’s DNE technology is proving to be such a powerful tool for site-specific genome editing,” said Precision BioSciences CEO Matthew Kane. “We look forward to applying our technique towards the generation of greatly needed therapeutics, research and bioproduction platforms, and agricultural products.”
About Precision BioSciences
Precision BioSciences’ mission is to continually provide, improve, and enable the world’s most powerful genome engineering technology. Precision’s proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.
Precision BioSciences’ vision is to be the conduit through which the world’s greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the world’s largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit www.precisionbiosciences.com.